Additional Details

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente
Torrance, CA 90502